Dosing of medications in morbidly obese patients in the intensive care unit setting
- PMID: 14625670
- DOI: 10.1007/s00134-003-2059-6
Dosing of medications in morbidly obese patients in the intensive care unit setting
Abstract
Objective: To derive recommendations for the dosing of commonly used medications in the morbidly obese patient in the ICU.
Data sources: Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references.
Study selection: All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients.
Data extraction: The emphasis was on studies involving morbidly obese patients but, in the absence of such data, investigations involving lesser forms of obesity were extracted.
Data synthesis: There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obese patient in the ICU, although recommendations were provided based on the available information.
Conclusions: There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.
Similar articles
-
Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.J Clin Pharm Ther. 2014 Dec;39(6):584-608. doi: 10.1111/jcpt.12200. Epub 2014 Sep 9. J Clin Pharm Ther. 2014. PMID: 25203631 Review.
-
Influence of Morbid Obesity on the Clinical Pharmacokinetics of Various Anti-Infective Drugs: Reappraisal Using Recent Case Studies-Issues, Dosing Implications, and Considerations.Am J Ther. 2018 Mar/Apr;25(2):e224-e246. doi: 10.1097/MJT.0000000000000401. Am J Ther. 2018. PMID: 26766291 Review.
-
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231153638. doi: 10.1177/10760296231153638. Clin Appl Thromb Hemost. 2023. PMID: 36760080 Free PMC article. Review.
-
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Clin Pharmacokinet. 2014 Aug;53(8):753-62. doi: 10.1007/s40262-014-0154-1. Clin Pharmacokinet. 2014. PMID: 24989061
-
Dose adjustment of anaesthetics in the morbidly obese.Br J Anaesth. 2010 Dec;105 Suppl 1:i16-23. doi: 10.1093/bja/aeq312. Br J Anaesth. 2010. PMID: 21148651 Review.
Cited by
-
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.J Thromb Thrombolysis. 2008 Jun;25(3):273-9. doi: 10.1007/s11239-007-0051-7. Epub 2007 May 28. J Thromb Thrombolysis. 2008. PMID: 17530465
-
Population Pharmacokinetics of Dasatinib in Healthy Subjects.Pharmaceuticals (Basel). 2024 May 23;17(6):671. doi: 10.3390/ph17060671. Pharmaceuticals (Basel). 2024. PMID: 38931339 Free PMC article.
-
Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Br J Clin Pharmacol. 2012 May;73(5):685-90. doi: 10.1111/j.1365-2125.2011.04159.x. Br J Clin Pharmacol. 2012. PMID: 22129454 Free PMC article. Review.
-
A real-world, multicenter assessment of drugs requiring weight-based calculations in overweight, adult critically ill patients.ScientificWorldJournal. 2013 Nov 30;2013:909135. doi: 10.1155/2013/909135. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24363625 Free PMC article.
-
Designing drug regimens for special intensive care unit populations.World J Crit Care Med. 2015 May 4;4(2):139-51. doi: 10.5492/wjccm.v4.i2.139. eCollection 2015 May 4. World J Crit Care Med. 2015. PMID: 25938029 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical